Nurtec ODT (rimegepant) is FDA-approved for both purposes. It can stop a migraine attack that’s already started (abortive use) and reduce how many migraines you get in the first place (preventive use). It was the first migraine medication approved for this dual role, which is why the question comes up so often.
How It Works for Both Roles
Nurtec belongs to a class of medications called CGRP receptor antagonists. During a migraine, your body releases a protein called CGRP that binds to receptors on your nerves and triggers pain signals. Nurtec blocks those receptors so CGRP can’t latch on. Think of it as filling the seats before CGRP arrives: if the receptors are already occupied, the pain signaling chain never gets started.
This same blocking action explains why the drug works in two different contexts. When you take it during an attack, it interrupts the pain cascade in progress. When you take it regularly on a schedule, it keeps those receptors consistently blocked so fewer attacks gain traction in the first place.
Dosing for Acute (Abortive) Treatment
For stopping a migraine that’s already underway, the dose is one 75 mg orally dissolving tablet taken as soon as the attack begins. You place it on your tongue and let it dissolve, no water needed. The maximum in any 24-hour period is a single 75 mg dose, so unlike some other migraine medications, there’s no option to take a second tablet if the first one doesn’t fully work.
In clinical trials, 20% of patients taking Nurtec were completely pain-free at two hours, compared to about 12% on placebo. The trials also measured relief from the “most bothersome symptom,” which patients self-identified as light sensitivity, sound sensitivity, or nausea. A significantly higher percentage of people on Nurtec were free of that symptom at the two-hour mark as well. These numbers may sound modest, but they’re consistent with how migraine abortive trials typically report: complete pain freedom is a strict endpoint, and many more patients experience meaningful pain reduction even if they don’t hit zero.
Dosing for Preventive Treatment
For prevention, the dose is 75 mg taken every other day on an ongoing schedule, regardless of whether you’re having a migraine that day. You take it with or without food.
In the key prevention trial, patients on Nurtec reduced their monthly migraine days by an average of 4.3 over 12 weeks, compared to a 3.5-day reduction in the placebo group. That roughly 1-day difference over placebo is statistically significant and, for someone averaging several migraines a month, can represent a meaningful quality-of-life improvement. The American Headache Society now considers CGRP-targeting therapies, including Nurtec, a first-line option for migraine prevention.
Using It for Both at the Same Time
One of the most practical aspects of Nurtec’s dual approval is that you can use it for prevention and still take it to treat a breakthrough attack. The updated label allows up to 18 doses per month, combining both preventive (every-other-day) doses and acute doses for attacks that break through. So if you’re already taking it every other day and a migraine hits on an “off” day, you can take a dose to treat that attack.
This simplifies treatment for people who previously needed two separate medications: one daily preventive plus a different drug for acute attacks. Having a single medication handle both roles means fewer drug interactions to worry about and one less prescription to manage.
Side Effects
Nurtec is generally well tolerated. In clinical trials, the most common side effect for both uses was nausea, occurring in about 2 to 3% of patients compared to under 1% on placebo. When used preventively, abdominal pain or indigestion also appeared in roughly 2.4% of patients versus 0.8% on placebo.
The medication is contraindicated if you’ve had a hypersensitivity reaction to rimegepant or any of its ingredients. Delayed serious allergic reactions have been reported, so any signs of a reaction, even days after taking a dose, warrant attention. The safety of treating more than 15 migraines in a 30-day period has not been established in trials.
Why the Dual Role Matters
Before Nurtec, the migraine treatment landscape was more segmented. Triptans worked only as abortive treatments. Monthly injections targeting CGRP worked only as preventives. Having a single oral medication that crosses both categories gives patients and prescribers more flexibility, particularly for people with episodic migraine who need prevention but also want a reliable rescue option. It’s worth noting that the preventive indication is specifically for episodic migraine in adults, not chronic migraine (defined as 15 or more headache days per month).